CAR-T effective, safe for certain patients with central nervous system-involved lymphoma

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.
The findings — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — showed no increased risk for cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome (ICANS) among these patients.
“Based on these results, patients with primary or secondary CNS lymphoma should be included in future CAR T-cell therapy

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.
The findings — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — showed no increased risk for cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome (ICANS) among these patients.
“Based on these results, patients with primary or secondary CNS lymphoma should be included in future CAR T-cell therapy